Bleeding disorder, a newly recognized adverse event following sacubitril/valsartan therapy
European Journal of Case Reports in Internal Medicine · 11.03.2026 · 13 (4)
DOI: 10.12890/2026_006178 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 11.03.2026. Verfasst von Yaser W Al-Omari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Prince Faisal Bin Alhussein Hospital, Ministry of Health, Zarqa-Rusaifeh, Jordan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Sacubitril/valsartan (Entresto) is the only currently approved angiotensin receptor–neprilysin inhibitor (ARNI) drug. It demonstrates important therapeutic outcomes in heart failure patients by reducing hospitalizations and deaths. ARNI is generally safe but concerns about adverse drug reactions (ADRs) exist. This report documents a potential bleeding disorder, evidenced by elevated prothrombin time (PT) and international normalized ratio (INR), as a newly identified ADR. Case description: Despite not receiving anticoagulant medication, three male heart failure patients had elevated PT/INR values within 14 days to four months of initiating Entresto 50 mg twice daily. Temporary discontinuation (dechallenging) of Entresto resulted in a decline in PT/INR, while it increased upon re-challenge in at least one patient. Laboratory findings showed varying degrees of anaemia, occasional renal and hepatic abnormalities, with normal platelet counts. Naranjo scores (6–8) support a probable causal relationship between Entresto and the bleeding tendency, warranting careful coagulation monitoring during treatment.
Conclusion
This case series explicitly identified a probable causal relationship between Entresto (ARNI) and a potential bleeding risk as evaluated by the Naranjo ADR probability scale. By highlighting this previously unidentified ADR, this report attempts to raise awareness among healthcare practitioners regarding the need for vigilant monitoring of coagulation parameters in high-risk patients, even without concomitant anticoagulant treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Prince Faisal Bin Alhussein Hospital, Ministry of Health, Zarqa-Rusaifeh, Jordan.
- Department of Internal Medicine, Prince Faisal Bin Alhussein Hospital, Ministry of Health, Zarqa-Rusaifeh, Jordan.
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Zitieren
APA
Al-Omari, Y. W., Mustafa, S. A., Saleh, A. H., & Abdel-Razaq, W. S. (2026). Bleeding disorder, a newly recognized adverse event following sacubitril/valsartan therapy. European Journal of Case Reports in Internal Medicine, 13(4). https://doi.org/10.12890/2026_006178
Vancouver
Al-Omari YW, Mustafa SA, Saleh AH, Abdel-Razaq WS. Bleeding disorder, a newly recognized adverse event following sacubitril/valsartan therapy. European Journal of Case Reports in Internal Medicine. 2026;13(4). doi:10.12890/2026_006178
BibTeX
@article{AlOmari2026,
author = {Al-Omari, Yaser W and Mustafa, Samer A and Saleh, Ali H and Abdel-Razaq, Wesam S},
title = {Bleeding disorder, a newly recognized adverse event following sacubitril/valsartan therapy},
journal = {European Journal of Case Reports in Internal Medicine},
year = {2026},
volume = {13},
number = {4},
doi = {10.12890/2026_006178}
}
EUVIMED